-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
The company has once again been recognized as one of the “Top 100 Globalized Pharmaceutical Enterprises.”
Category:
Time：2018-11-07
From June 20 to 22, 2018, the 18th "World Pharmaceutical Ingredients China Exhibition" was grandly held at the Shanghai New International Expo Center. During the exhibition, the list of the Top 100 Chinese Pharmaceutical Companies Going Global in 2018 was unveiled. Shijiazhuang Sihua Pharmaceutical Co., Ltd. was honored to be included on the list and received the award for "Leading Enterprise in Formulation Internationalization."
From June 20 to 22, 2018, the 18th “World Pharmaceutical Ingredients China Exhibition” was grandly held at the Shanghai New International Expo Center. During the exhibition, the list of the Top 100 Chinese Pharmaceutical Companies Going Global for 2018 was unveiled. Shijiazhuang Fourth Pharmaceutical Co., Ltd. was honored to be included on the list and received the award for “Leading Enterprise in Formulation Internationalization.” This marks the second consecutive year that the company has been recognized with this prestigious honor, reflecting the industry’s high regard for the company’s business development and further demonstrating, through its strong performance, the brand influence and corporate value of Shijiazhuang Fourth Pharmaceutical.
It is understood that the selection of China’s Top 100 Internationalized Pharmaceutical Enterprises is organized by the China Chamber of Commerce for Import & Export of Medicines & Health Products. The event aims to recognize the outstanding contributions made by Chinese pharmaceutical companies in the global pharmaceutical industry chain. To date, this award has gained widespread recognition within the global pharmaceutical industry and enjoys broad social influence.
Through relentless efforts, the company has been making rapid strides in the international market in recent years. In 2017, the company successfully obtained six international quality certifications and approvals, including TGA from Ethiopia, the Philippines, and Australia, as well as IDA from the Netherlands. To date, the company has achieved product registrations in a total of 80 countries, with a portfolio of 96 registered product specifications and varieties. Currently, the company has fully aligned itself with international advanced standards in areas such as R&D capabilities, equipment and process technologies, environmental protection standards, and patent protection.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license